A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
← catalyst calendarNCT05906992 · readout ≤ 193 d
Sponsored by Celltrion (industry) · 068270.KS — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
512estimated
Sites
1
Country
Poland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-11 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2023-06-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsing-remitting Multiple Sclerosis
Interventions
- Biological: CT-P53 — also filed as Ocrelizumab
- Biological: US-Ocrevus — also filed as Ocrelizumab
- Biological: EU-Ocrevus — also filed as Ocrelizumab
Primary outcomes
what the primary-completion date above is the date OFArea under the concentration-time curve in PK group
measured Up to Week 24
Total number of new GdE lesions on T1-weighted brain MRI in Main study group
measured Up to Week 24
Permalink · 068270.KS's whole pipeline · Catalyst calendar · Every registered study · What changed